Submitted:
18 October 2024
Posted:
19 October 2024
Read the latest preprint version here
Abstract
Keywords:
1. Introduction
2. Results
2.1. Patient characteristics
2.2. Blood culture information
2.3. Contaminated and indeterminate blood cultures
2.4. Quality indicators
2.5. Care bundle compliance
2.6. Factors associated with BC contamination
- Blood culture set-specific risk factors
- Patient-specific risk factors
3. Discussion
4. Materials and Methods
4.1. Setting
4.2. Study design
4.3. Inclusion / exclusion criteria
4.4. Data collection
4.5. Intervention: Care bundle implementation.
4.6. Definitions and outcomes
4.7. Statistical analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Suetens, C.K., T.; Plachouras, D. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2022-23.; European Centre for Disease Prevention and Control.: Stockholm, 2024.
- Wilson, M.L. Principles and Procedures for Blood Cultures ( CLSI guideline M47), 2nd ed.; Clinical and Laboratory Standards Institute: 2022.
- Miller, J.M.; Binnicker, M.J.; Campbell, S.; Carroll, K.C.; Chapin, K.C.; Gonzalez, M.D.; Harrington, A.; Jerris, R.C.; Kehl, S.C.; Leal, S.M., Jr.; et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clinical infectious diseases 2024. [CrossRef]
- Kirn, T.J.; Weinstein, M.P. Update on blood cultures: how to obtain, process, report, and interpret. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2013, 19, 513-520. [CrossRef]
- Ko, B.S.; Choi, S.H.; Shin, T.G.; Kim, K.; Jo, Y.H.; Ryoo, S.M.; Park, Y.S.; Kwon, W.Y.; Choi, H.S.; Chung, S.P.; et al. Impact of 1-Hour Bundle Achievement in Septic Shock. J Clin Med 2021, 10, 527. [CrossRef]
- Story-Roller, E.; Weinstein, M.P. Chlorhexidine versus Tincture of Iodine for Reduction of Blood Culture Contamination Rates: a Prospective Randomized Crossover Study. Journal of clinical microbiology 2016, 54, 3007-3009. [CrossRef]
- Washer, L.L.; Chenoweth, C.; Kim, H.W.; Rogers, M.A.; Malani, A.N.; Riddell, J.t.; Kuhn, L.; Noeyack, B., Jr.; Neusius, H.; Newton, D.W.; et al. Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. Infection control and hospital epidemiology 2013, 34, 15-21. [CrossRef]
- Doern, G.V.; Carroll, K.C.; Diekema, D.J.; Garey, K.W.; Rupp, M.E.; Weinstein, M.P.; Sexton, D.J. Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. Clinical microbiology reviews 2019, 33, e00009-00019. [CrossRef]
- Schinkel, M.; Boerman, A.; Carroll, K.; Cosgrove, S.E.; Hsu, Y.J.; Klein, E.; Nanayakkara, P.; Schade, R.; Wiersinga, W.J.; Fabre, V. Impact of Blood Culture Contamination on Antibiotic Use, Resource Utilization, and Clinical Outcomes: A Retrospective Cohort Study in Dutch and US Hospitals. Open forum infectious diseases 2024, 11, ofad644. [CrossRef]
- Hughes, J.A.C., C.J.; Williams, J.; Ray, M.; Coyer, F. Interventions to reduce peripheral blood culture contamination in acute care settings: A systematic review and meta-analysis. MedRxiv 2023. [CrossRef]
- Kai, M.; Miyamoto, K.; Akamatsu, K.; Tsujita, A.; Nishio, M. Effect of a bundle-approach intervention against contamination of blood culture in the emergency department. Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy 2020, 26, 785-789. [CrossRef]
- Minami, K.; Yamada, T.; Yoshioka, K.; Kawanishi, F.; Ogawa, T.; Ukimura, A. Effect of the introduction of a management bundle for blood culture collection. American journal of infection control 2022, 50, 772-776. [CrossRef]
- Murphy, T.; Maile, D.; Barsch, T.; Jerdan, F. Investigating the impact of blood culture bundles on the incidence of blood culture contamination rates. J Infus Nurs 2014, 37, 205-210. [CrossRef]
- What are the key infection prevention and control recommendations to inform a prevention of blood culture contamination. Antimicrobial Resistance and Healthcare Associated Infection Scotland. Available online: https://www.nss.nhs.scot/media/2276/3_blood-culture-review-v3.pdf (accessed on 02/09/2024).
- Ista, E.; van der Hoven, B.; Kornelisse, R.F.; van der Starre, C.; Vos, M.C.; Boersma, E.; Helder, O.K. Effectiveness of insertion and maintenance bundles to prevent central-line-associated bloodstream infections in critically ill patients of all ages: a systematic review and meta-analysis. Lancet Infect Dis 2016, 16, 724-734. [CrossRef]
- Country factsheet Greece: Key indicators. Point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals, 2022-2023. Available online: https://www.ecdc.europa.eu/en/publications-data/country-factsheet-greece (accessed on 02/09/2024).
- Gilhooly, D.; Green, S.A.; McCann, C.; Black, N.; Moonesinghe, S.R. Barriers and facilitators to the successful development, implementation and evaluation of care bundles in acute care in hospital: a scoping review. Implement Sci 2019, 14, 47. [CrossRef]
- Karapanou, A.; Vieru, A.M.; Sampanis, M.A.; Pantazatou, A.; Deliolanis, I.; Daikos, G.L.; Samarkos, M. Failure of central venous catheter insertion and care bundles in a high central line-associated bloodstream infection rate, high bed occupancy hospital. American journal of infection control 2020, 48, 770-776. [CrossRef]
- Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals. Available online: https://www.cdc.gov/labquality/blood-culture-contamination-prevention.html (accessed on 14-09-2024).
- BACTEC™ Standard/10 Aerobic/F Culture Vials Instructions for use. Available online: http://static.bd.com/documents/eifu/500017524_ZMG_E_RL_500017524.pdf (accessed on 02-09-2024).
- Klucher, J.M.; Davis, K.; Lakkad, M.; Painter, J.T.; Dare, R.K. Risk factors and clinical outcomes associated with blood culture contamination. Infection control and hospital epidemiology 2022, 43, 291-297. [CrossRef]
- Liaquat, S.; Baccaglini, L.; Haynatzki, G.; Medcalf, S.J.; Rupp, M.E. Patient-specific risk factors contributing to blood culture contamination. Antimicrob Steward Healthc Epidemiol 2022, 2, e46. [CrossRef]
- Blood Culture Contamination - An Overview for Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory. Available online: https://www.cdc.gov/antibiotic-use/core-elements/pdfs/fs-bloodculture-508.pdf (accessed on 02-09-2024).
- Common commensals - National Health Safety Network Organism List. Available online: https://www.cdc.gov/nhsn/xls/master-organism-com-commensals-lists.xlsx (accessed on 02-09-2024).
- Weinstein, M.P. Blood culture contamination: persisting problems and partial progress. Journal of clinical microbiology 2003, 41, 2275-2278. [CrossRef]
- Cruz, M.; Pinto-Orellana, M.A.; Gillen, D.L.; Ombao, H.C. RITS: a toolbox for assessing complex interventions via interrupted time series models. BMC Med Res Methodol 2021, 21, 143. [CrossRef]
- Chen, L.F.; Vander Weg, M.W.; Hofmann, D.A.; Reisinger, H.S. The Hawthorne Effect in Infection Prevention and Epidemiology. Infection control and hospital epidemiology 2015, 36, 1444-1450. [CrossRef]
- Bruchez, S.A.; Duarte, G.C.; Sadowski, R.A.; Custodio da Silva Filho, A.; Fahning, W.E.; Belini Nishiyama, S.A.; Bronharo Tognim, M.C.; Cardoso, C.L. Assessing the Hawthorne effect on hand hygiene compliance in an intensive care unit. Infect Prev Pract 2020, 2, 100049. [CrossRef]
- Richter, S.S.; Beekmann, S.E.; Croco, J.L.; Diekema, D.J.; Koontz, F.P.; Pfaller, M.A.; Doern, G.V. Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. Journal of clinical microbiology 2002, 40, 2437-2444. [CrossRef]
- Weinstein, M.P.; Towns, M.L.; Quartey, S.M.; Mirrett, S.; Reimer, L.G.; Parmigiani, G.; Reller, L.B. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clinical infectious diseases 1997, 24, 584-602. [CrossRef]
- Hills, A.Z.; Ray, M.; Williams, J.; Greenslade, J. Benchmarking blood culture quality in the emergency department: Contamination, single sets and positivity. Emergency medicine Australasia : EMA 2024, 36, 206-212. [CrossRef]
- Gonsalves, W.I.; Cornish, N.; Moore, M.; Chen, A.; Varman, M. Effects of volume and site of blood draw on blood culture results. Journal of clinical microbiology 2009, 47, 3482-3485. [CrossRef]

| PRE (n=419; 56.1%) | POST (n=328; 43.9%) | P value | |
| Age, (mean, SD) | 61.2 (16.7) | 60.5 (16.9) | 0.711‡ |
| Male gender | 238 (56.8) | 210 (64) | 0.054+ |
| Patients with blood culture | 255 (60.9) | 211 (64.3) | 0.331* |
| Hospital admission to ICU, days (median, IQR) | 3 (0 - 7) | 3 (1 - 10) | 0.091§ |
| Days in ICU, (median, IQR) | 6 (2 - 19) | 7 (2 - 18) | 0.313§ |
| Days in hospital, (median, IQR) | 22 (11 - 47) | 27 (12 - 56.5) | 0.131§ |
| Death during hospitalization | 158 (37.8) | 112 (34.1) | 0.303* |
| Charlson Comorbidity Index, | 0 (0- 4) | 0 (0 - 4) | 0.733§ |
| Prosthetic heart valve | 7 (1.7) | 5 (1.5) | 0.875* |
| Pacemaker | 8 (1.9) | 5 (1.5) | 0.690* |
| Vascular implant or stent | 15 (3.6) | 12 (3.7) | 0.954* |
| Orthopaedic endoprosthesis | 5 (1.2) | 3 (0.9) | >0.999† |
| APACHE II at admission (median, IQR) | 10 (0 - 17) | 10 (0 - 17.5) | 0.547§ |
| SOFA at admission (median, IQR) | 6 (0 - 9) | 6 (0 - 10) | 0.668§ |
| Short-term CVC | 242 (57.8) | 202 (61.6) | 0.290* |
| Tunneled CVC | 0 (0) | 3 (0.9) | 0.084† |
| Biliary or urinary drainage or stent | 4 (1) | 8 (2.4) | 0.109* |
| Wound drainage tubes | 102 (24.3) | 59 (18) | 0.036* |
| Peritoneal dialysis catheter | 1 (0.2) | 0 (0) | >0.999† |
| Urinary bladder catheter | 250 (59.7) | 216 (65.9) | 0.083* |
| Intubation | 223 (53.2) | 187 (57) | 0.302* |
| CRRT | 68 (16.2) | 46 (14) | 0.406* |
| Respiratory infection | 102 (24.3) | 62 (18.9) | 0.075* |
| Urinary tract infection | 3 (0.7) | 4 (1.2) | 0.705† |
| Intra-abdominal infection | 19 (4.5) | 9 (2.7) | 0.201* |
| Skin and soft tissue infection | 18 (4.3) | 7 (2.1) | 0.103* |
| CNS infection | 7 (1.7) | 4 (1.2) | 0.763† |
| Surgical site infection | 1 (0.2) | 1 (0.3) | >0.999† |
| PRE phase | POST phase | TOTAL | |
|---|---|---|---|
| BLOOD CULTURE SETS | |||
| Positive | 164 (18.6%) | 150 (17%) | 314 (17.8%) |
| Monomicrobial | 138 (15.6%) | 140 (15.9%) | 278 (15.8%) |
| Polymicrobial | 26 (2.9%) | 10 (1.1%) | 36 (2%) |
| Common commensal | 73 (8.3%) | 21 (2.4%) | 94 (5.3%) |
| Contaminated | 26 (2.9%) | 7 (0.8%) | 33 (1.9%) |
| Indeterminate | 47 (5.3%) | 14 (1.6%) | 61 (3.5%) |
| Negative | 645 (73.1%) | 710 (80.6%) | 1355 (76.9%) |
| Subtotal | 882 (100%) | 881 (100%) | 1763 (100%) |
| SOLITARY VIALS | |||
| Positive | 52 (15.9%) | 9 (7.8%) | 61 (13.8%) |
| Monomicrobial | 44 (13.4%) | 6 (5.2%) | 50 (11.3%) |
| Polymicrobial | 8 (2.4%) | 3 (2.6%) | 11 (2.5%) |
| Common commensal | 19 (5.8%) | 1 (0.9%) | 20 (4.5%) |
| Contaminated | 3 (0.9%) | 0 (0%) | 3 (0.7%) |
| Indeterminate | 16 (4.9%) | 1 (0.9%) | 17 (3.8%) |
| Negative | 257 (78.4%) | 105 (91.3%) | 362 (81.7%) |
| Subtotal | 328 | 115 | 443 |
| ALL SETS | |||
| Positive | 216 (17.9%) | 159 (16%) | 375 (17%) |
| Monomicrobial | 182 (15%) | 146 (14.7%) | 328 (14.9%) |
| Polymicrobial | 34 (2.8%) | 13 (1.3%) | 47 (2.1%) |
| Common commensal | 92 (7.6%) | 22 (2.2%) | 114 (5.2%) |
| Contaminated | 29 (2.4%) | 7 (0.7%) | 36 (1.6%) |
| Indeterminate | 63 (5.2%) | 15 (1.5%) | 78 (3.5%) |
| Negative | 902 (74.5%) | 815 (81.8%) | 1717 (77.8%) |
| TOTAL | 1210 | 996 | 2206 |
| Risk factors for contaminated BC | Category | Contaminated BC set, n (%) | Negative BC set, n (%) | Chi-square, p value | Odds ratio (95% CI) |
|---|---|---|---|---|---|
| Age (mean, SD) | n/a | 59.0 (53.0-69.0) | 64.0 (47.0-74) | 0.75 | n/a |
| Sex | Female | 4 (2,2) | 182 (97,8) | 0.14 | 3.74 (1.24-11.24) |
| Male | 18 (7,6) | 219 (92,4) | |||
| ICU Section | Medical | 17 (6,7) | 238 (93,3) | 0.118 | 0.43 (0.15-1.19) |
| Surgical | 5 (3) | 163 (97) | |||
| Charlson Comorbidity index† | n/a | 2.0 (1.0-6.0) | 3.0 (1.0-5.0) | 0.91 | n/a |
| Chronic dialysis | No | 18 (4,4) | 388 (95,6) | 0.008 | 6.63 (1.97-22.38) |
| Yes | 4 (23,5) | 13 (76,5) | |||
| Asplenia | No | 22 (5,2) | 398 (94,8) | 1.0 | n/a |
| Yes | 0 (0) | 3 (100) | |||
| HIV (no AIDS) | No | 22 (5,3) | 396 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 5 (100) | |||
| Bone marrow transplant | No | 22 (5,3) | 392 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 9 (100) | |||
| Solid organ transplant | No | 22 (5,3) | 395 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 6 (100) | |||
| BMI<18.5 | No | 22 (5,3) | 397 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 4 (100) | |||
| Prosthetic heart valve | No | 22 (5,3) | 392 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 9 (100) | |||
| Pacemaker | No | 22 (5,3) | 392 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 9 (100) | |||
| Vascular implant or stent | No | 21 (5,2) | 380 (94,8) | 1.0 | 0.86 (0.11-6.72) |
| Yes | 1 (4,5) | 21 (95,5) | |||
| Orthopaedic endoprosthesis | No | 22 (5,3) | 393 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 8 (100) | |||
| APACHE II on admission† | 16.0 (11.0-23.0) | 15.00 (11.0-20.0) | 0.44 | ||
| SOFA on admission† | 9.0 (8.0-11.0) | 8.0 (7.0-11.0) | 0.29 | ||
| SOFA on BC day†* | 9.0 (6.0-11.0) | 9.0 (5.5-11.0) | 0.65 | ||
| Albumin on admission† | 3.3 (2.6-3.9) | 3.0 (2.5-3.6) | 0.19 | ||
| CRP on admission† | 9.2 (1.0-31.5) | 8.4 (2.0-19.1) | 0.48 | ||
| Albumin on BC day†* | 2.5 (2.2-3.2) | 2.6 (2.2-3.1 | 0.94 | ||
| CRP on BC day†* | 8.1 (6.3-18.7) | 13.1 (6.4-18,3) | 0.30 | ||
| Chemotherapy | No | 19 (4,8) | 373 (95,2) | 0.21 | 2.1 (0.59-7.54) |
| Yes | 3 (9,7) | 28 (90,3) | |||
| Corticosteroids | No | 20 (5,2) | 365 (94,8) | 1.0 | 1.01 (0.23-4.51) |
| Yes | 2 (5,3) | 36 (94,7) | |||
| Short-term CVC | No | 0 (0) | 28 (100) | 0.38 | n/a |
| Yes | 22 (5,6) | 373 (94,4) | |||
| Implantable CVC | No | 22 (5,2) | 398 (94,8) | 1.0 | n/a |
| Yes | 0 (0) | 3 (100) | |||
| Biliary or urinary drainage or stent | No | 22 (5,3) | 390 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 11 (100) | |||
| Wound drainage tubes | No | 18 (6,5) | 257 (93,5) | 0.109 | 0.39 (0.13-1.19) |
| Yes | 4 (2,7) | 144 (97,3) | |||
| Peritoneal dialysis catheter | No | 22 (5,2) | 399 (94,8) | 1.0 | n/a |
| Yes | 0 (0) | 2 (100) | |||
| Urinary bladder catheter | No | 0 (0) | 7 (100) | 1.0 | n/a |
| Yes | 22 (5,3) | 394 (94,7) | |||
| Intubation | No | 2 (3,4) | 56 (96,6) | 0.75 | 1.62 (0.37-7.14) |
| Yes | 20 (5,5) | 345 (94,5) | |||
| CRRT | No | 18 (5,6) | 302 (94,4) | 0.61 | 0.68 (0.22-2.05) |
| Yes | 4 (3,9) | 99 (96,1) | |||
| Respiratory infection | No | 17 (6,1) | 260 (93,9) | 0.26 | 0.54 (0.19-1.50) |
| Yes | 5 (3,4) | 141 (96,6) | |||
| Urinary tract infection | No | 22 (5,3) | 396 (94,7) | 1.0 | n/a |
| Yes | 0 (0) | 5 (100) | |||
| Intra-abdominal infection | No | 22 (5,5) | 379 (94,5) | 0.61 | n/a |
| Yes | 0 (0) | 22 (100) | |||
| Skin and soft tissue infection | No | 22 (5,5) | 379 (94,5) | 0.61 | n/a |
| Yes | 0 (0) | 22 (100) | |||
| CNS infection | No | 21 (5,1) | 392 (94,9) | 0.41 | 2.07 (0.25-17.14) |
| Yes | 1 (10) | 9 (90) | |||
| CR-BSI | No | 22 (5,2) | 400 (94,8) | 1.0 | n/a |
| Yes | 0 (0) | 1 (100) | |||
| Surgical site infection | No | 22 (5,2) | 399 (94,8) | 1.0 | n/a |
| Yes | 0 (0) | 2 (100) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).